Hope S. Rugo, MD, FASCO, is professor of medicine in the Division of Hematology and Oncology at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, where she is also the director of Breast Oncology and Clinical Trials Education.
TROPION-Breast01: DatoDXd in Previously Treated Inoperable/Metastatic HR+/HER2- Breast Cancer
January 8th 2024Medical oncologists discuss results from the TROPION-Breast01 study investigating Dato-DXd (datopotamab deurxtecan) in patients with previously treated inoperable or metastatic HR+/HER2- breast cancer.
Results from INAVO120 in PIK3CA-Mutated HR+/HER2- Locally Advanced/Metastatic Breast Cancer
January 8th 2024Hope Rugo, MD, and the Oncology Brothers review results from the INAVO120 trial studying inavolisib in combination with palbociclib and fulvestrant in PIK3CA-mutated HR+/HER2- locally advanced or metastatic breast cancer.
MONARCH 3: First-Line Abemaciclib Plus Nonsteroidal AI for HR+/HER2- Advanced Breast Cancer
January 8th 2024Experts on breast cancer review the final overall survival results from MONARCH 3 investigating abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+/HER2- advanced breast cancer.
Final iDFS Analysis from NATALEE in HR+/HER2- Early Breast Cancer
January 8th 2024Following SABCS 2023, Hope Rugo, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the final invasive disease-free survival analysis from the NATALEE trial in HR+/HER2- early breast cancer.
KEYNOTE-522 Demonstrates Potential for Immunotherapy in Triple-Negative Breast Cancer
November 1st 2019Hope S. Rugo, MD, discusses the potential role of immunotherapy for the treatment of patients with triple-negative breast cancer (TNBC), based on data from the KEYNOTE-522 clinical trial. Immunotherapy has been very exciting in this setting.
Five-Year Dosing, Efficacy Results for Nab-Paclitaxel in TNBC
January 10th 2018Hope S. Rugo, MD, a medical oncologist and Director of the Breast Oncology Clinical Trials Program at University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses 5-year follow-up data from the CALGB 40502//NCCTG N063H study, which was a randomized phase III trial of weekly paclitaxel (Abraxane) compared with nab-paclitaxel or ixabepilone (Ixempra) with bevacizumab (Avastin) as first-line chemotherapy for locally recurrent or metastatic breast cancer.